Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-α1-antichymotrypsin complex together with free or total PSA

Clinical Chemistry

Volumn 49, Issue 1, 2003, Pages 97-103

  Zhu, Lei ^a   Leinonen, Jari ^a   Zhang, Wan Ming ^a   Finne, Patrik ^a   Stenman, Ulf Håkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; CATHEPSIN; EUROPIUM; PROSTATE SPECIFIC ANTIGEN; SAMARIUM;

ADSORPTION; ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ARTICLE; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME ASSAY; ENZYME IMMUNOASSAY; ENZYME SPECIFICITY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; ISOTOPE LABELING; PROBLEM SOLVING; SOLID; VALIDATION PROCESS;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; ANIMALS; ANTIBODIES, MONOCLONAL; FALSE POSITIVE REACTIONS; FEMALE; FLUOROIMMUNOASSAY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0037235237     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.1.97     Document Type: Article

References (28)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urol 1979;17:159-63.
2. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 1986;83:3166-70.
3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
4. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
5. Oesterling JE. Prostate-specific antigen: a valuable clinical tool. Oncology (Huntingt) 1991;5:107-22.
6. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
7. Hetherington JW, Siddall JK, Cooper EH. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer. Eur Urol 1988;14:1-5.
8. Armitage TG, Cooper EH, Newling DW, Robinson MR, Appleyard I. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol 1988;62:584-9.
9. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
10. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-91.
11. Christensson A, Björk T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
12. 1-protease inhibitor in serum. Clin Chem 1999;45:814-21.
13. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
14. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
15. 1-antichymotrypsin. Clin Chem 1993;39:2098-103.
16. 1-antichymotrypsin complex. Clin Chem 1995;41:1480-8.
17. Wu JT, Zhang P, Liu GH, Wilson L. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal 1998;12:14-9.
18. Stenman UH, Paus E, Allard WJ, Andersson I, Andres C, Barnett TR, et al. Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999;20:1-12.
19. Zhang W-M, Leinonen J, Kalkkinen N, Dowell B, Stenman U-H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995;41:1567-73.
20. Zhang WM, Leinonen J, Kalkkinen N, Stenman U-H. Prostate-specific antigen forms a complex with and cleaves α1-protease inhibitor in vitro. Prostate 1997;33:87-96.
21. Espana F, Martinez M, Sanchez-Cuenca J, Vera CD, Estelles A, Jimenez-Cruz JF. Prostate-specific antigen and its complexes with α1-antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol 1996;30:512-8.
22. Björk T, Piironen T, Pettersson K, Lövgren T, Stenman U-H, Oesterling JE, et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996;48:882-8.
23. 1-antichymotrypsin in plasma. Clin Chem 1993;39:869-74.
24. Wang TJ, Linton HJ, Payne J, Liu R-S, Kuus-Reichet K, Rittenhouse HG, et al. Development of monoclonal antibodies specific for the PSA-ACT complex and their incorporation into an immunoassay [Abstract]. Clin Chem 1997;43:550.
25. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372-8.
26. Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 2000;163:119-26.
27. Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000;46:55-62.
28. Finne P, Zhang WM, Auvinen A, Leinonen J, Maattanen L, Rannikko S, et al. Use of the complex between prostate specific antigen and α1-protease inhibitor for screening prostate cancer. J Urol 2000;164:1956-60.